FDA should begin safety and efficacy reviews for all DESI drugs, HRG urges.
Executive Summary
FDA SHOULD CONDUCT SAFETY, EFFICACY REVIEW OF ALL DESI DRUGS, HRG maintains, beginning with the "most heavily prescribed drugs," the consumer advocate group urges in a May 29 letter to the agency. "Hundreds of millions of consumer dollars a year are at stake," Public Citizen's Health Research Group asserts in the letter, referring to brand name pharmaceuticals marketed prior to 1938.